Comparing the therapeutic outcome of different alpha-blocker treatments for BPH in the same individuals

International Urology and Nephrology

Volumn 40, Issue 3, 2008, Pages 663-666

  Senkul, Temucin ^a   Yilmaz, Omer ^a   Iseri, Cuneyt ^a   Adayener, Cuneyt ^a   Akyol, Ilker ^a   Ates, Ferhat ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Alpha blocker; BPH; Comparison; Treatment

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; PROSTATE SPECIFIC ANTIGEN; TERAZOSIN;

ABSENCE OF SIDE EFFECTS; ADULT; ANAMNESIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; DIZZINESS; DRUG EFFICACY; ECHOGRAPHY; HOSPITAL DEPARTMENT; HUMAN; LOWER URINARY TRACT SYMPTOM; MALE; MEDICAL DECISION MAKING; MEDICAL LITERATURE; OUTCOME ASSESSMENT; PROSTATE HYPERTROPHY; TREATMENT DURATION; TREATMENT OUTCOME; UROFLOWMETRY;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; PRAZOSIN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; QUINAZOLINES; TREATMENT OUTCOME;

EID: 48549087201     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11255-007-9312-9     Document Type: Article

References (12)

1. Chute CG, Pander LA, Girman CJ et al (1993) The prevalence of prostatism: A population-based survey of urinary symptoms. J Urol 150:85-89
2. Chapple CR (2005) A comparison of varying α-blockers and other pharmacotherapy options for lower urinary tract symptoms. Rev Urol 4(Suppl 7):22-30
3. Djoko R, Doddy MS, Suwandi S et al (2006) Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia. Int J Urol 13:1405-1409
4. Toshihiko T (2000) Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: A short-term open, randomized multicenter study. Int J Urol 7:199-205
5. Reijke TM, Klarskov P (2004) Comparatice efficacy of two alpha1-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement. BJU Int 93:757-762
6. Shargel L, Wu-Pong S, Yu A (2004) Applied biopharmaceutics and pharmacokinetics, 5th edn. McGraw-Hill, New York
7. Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ (2004) EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 46(5):547-554
8. Fourcade RO (2000) Efficiency and tolerance of terazosine in ambulatory patients with benign prostatic hypertrophy: Comparative randomized and double-blind trial versus alfuzosin. The MG Terazosine Group Prog Urol 10(2):246-253
9. Larosa M, Ferretti S, Salsi P, Simonazzi M (1994) Use of terazosin and alfuzosin in the treatment of benign prostatic hypertrophy (BPH): Our experience. Acta Biomed Ateneo Parmense 65(1-2):23-28
10. Djavan B, Marberger M (1999) A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 36(1):1-13
11. Milani S, Djavan B (2005) Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Latest update on alpha-adrenoceptor antagonists. BJU Int 95(Suppl 4):29-36
12. Lepor H (2006) The evolution of alpha-blockers for the treatment of benign postatic hyperplasia. Rev Urol 8(Suppl 4):S3-S9